Figure 6.

EPO increases recruitment of Ly6C^hi monocytes and neutrophils during AILI. (A) Liver non-parenchymal cells were analyzed by multi-parameter flow cytometry. The gating strategy for the definition of CD11b⁺ (myeloid cells) or CD11b⁻ (lymphocytes) in the APAP-challenged livers was defined by using CD45, F4/80 and CD11b. Bar graphs indicate CD11b⁺/ CD11b⁻ cell ratio from diluent (control) or EPO-injected mice, 24 h or 48 h post injection with APAP, N = 5, **p < 0.01, *p < 0.05. (B) Serum CCL2 levels detected by ELISA in diluent (control) or EPO-injected mice, 24 h or 48 h after treatment with APAP, N = 4–10, *p ≤ 0.05. (C) Liver non-parenchymal cells were analyzed by flow cytometry. The gating strategy for the definition of Ly6C^hi monocytes or neutrophils in the APAP-challenged liver was defined by using CD45, F4/80, CD11b, Ly6C, CX₃CR1 and MHCII. Bar graphs indicate Ly6C^hi monocytes or neutrophils as a percent of CD45⁺ liver cells from diluent (control) or EPO-injected mice, 24 h or 48 h post injection with APAP, N = 4–10, *p < 0.05. All graphs represent mean ± SEM.